Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY) posted 54% revenue growth driven by ...
The explosion in use of GLP-1 medicines for Type 2 diabetes control could be a boon, not a threat, to companies like North Chicago-based Abbott and other makers of continuous glucose monitors. Abbott ...
Shares of diabetes medical device makers climbed Wednesday afternoon after Abbott Laboratories CEO Robert Ford downplayed fears that GLP-1 drugs would cut into its business, instead suggesting that ...
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback